课题基金 / 基金详情

DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES

DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
多西尔
批准号：
6305818
负责人：
CAROLYN WASSERHEIT
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6305818
关键词：
clinical research clinical trial phase I combination cancer therapy dosage doxorubicin drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer relapse /recurrence paclitaxel pharmacokinetics

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
该I期临床试验由研究者发起，适用于已确诊恶性肿瘤且无有效治疗方法或已接受治疗且疾病复发时间小于1年的患者。目的是确定每21天30mg /m2的固定剂量与Doxil联合给药的最大耐受剂量。剂量限制毒性，抗肿瘤活性和药代动力学也将被确定。
英文摘要
This phase I investigator-initiated trial is for patients who have confirmed malignancy for which an effective therapy is unavailable or was already used with disease recurrence in < one year. The objectives are to determine the maximal tolerated dose of Taxotere that can be administered in combination with Doxil at a fixed dose of 30 mg/m2 every 21 days. Dose-limiting toxicity, antitumor activity and pharmacokinetics will be also be determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXORUBICIN AND EDATREXATE IN THE TREATMENT OF SOLID TUMORS
海外基金